Genelux financials
$2.45−0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $8.0K | $8.0K | $170.0K |
| Gross profit | $8.0K | $8.0K | $170.0K |
| Gross margin | 100.0% | 100.0% | 100.0% |
| Operating income | -$33.2M | -$31.7M | -$24.2M |
| Net income | -$32.1M | -$29.9M | -$28.3M |
| Net margin | −401812.5% | −373362.5% | −16645.3% |
| Diluted EPS | $-0.86 | $-0.95 | $-1.16 |
| EBITDA | -$33.0M | -$31.5M | -$23.7M |
| Operating cash flow | -$25.3M | -$21.2M | -$20.3M |
| Free cash flow | -$26.4M | -$21.6M | -$21.3M |
| Diluted shares | 37.2M | 31.5M | 24.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $5.3M | $8.6M | $9.4M |
| Short-term investments | $9.3M | $22.3M | $13.8M |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $19.0M | $34.7M | $27.9M |
| Total liabilities | $7.5M | $8.4M | $8.4M |
| Shareholders' equity | $11.5M | $26.3M | $19.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology